Myths vs facts: CYP2C19 and Blutzucker

The claim that CYP2C19 directly regulates blood sugar is a myth. CYP2C19 is a liver enzyme primarily involved in drug metabolism (e.g., clopidogrel, proton pump inhibitors, certain antidepressants). There is no robust, causal evidence linking CYP2C19 variants to fasting glucose, insulin resistance, or diabetes risk. Some indirect associations (e.g., PPIs altering gut microbiome and glucose metabolism) are weak and inconsistent. Consumer DNA tests that imply a direct effect on blood sugar overstate the science. Blood sugar homeostasis is governed by insulin, glucagon, lifestyle, and well-established genes (e.g., TCF7L2, GCK). For improving blood sugar, focus on diet, exercise, and medical monitoring—not CYP2C19 genotypes. Evidence: mechanistic/weak, no clinical validation.